Jasper Therapeutics, Inc.

JSPR

$48M

Micro Cap

NASDAQBiotechnology🇺🇸North America27 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 1, 2026

14w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Briquilimab	Phase 2	Chronic Spontaneous Urticaria	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Apr 1, 2026Briquilimab

Primary completion for Briquilimab trial (NCT06162728) in Chronic Spontaneous Urticaria

Regulatory Approvals

JSPR News